Home / Science / Scientist Tackles Vitiligo Beyond Skin Deep
Scientist Tackles Vitiligo Beyond Skin Deep
8 Jul
Summary
- Dr. Parul Ganju pivoted from traditional research to developing a vitiligo cure.
- Ahammune Biosciences' drug candidate AB1001 targets the disease's root cause.
- The drug is advancing through clinical trials, offering new hope to millions.
Dr. Parul Ganju chose an unconventional path, dedicating her scientific career to developing a cure for vitiligo. After earning her PhD, she recognized the extensive impact of the autoimmune condition beyond skin appearance, motivating her to find effective treatments.
In 2016, Dr. Ganju co-founded Ahammune Biosciences in Pune. The company's lead drug candidate, AB1001, is designed to directly target the destruction of melanocytes, offering a novel approach compared to existing immune-suppressing medications.
AB1001 has successfully completed Phase 1 clinical trials and progressed to Phase 2. Ahammune Biosciences has secured international patents and raised approximately 8 million US dollars from investors, signaling confidence in its therapeutic potential.
This development coincides with World Allergy Day, highlighting the importance of advancing research into immune-related disorders. Dr. Ganju's journey exemplifies a purpose-driven career, prioritizing patient impact over traditional academic prestige.
